A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

May 10, 2011

Statin Drugs Reduce Inflammation Linked to Heart Disease

Treatment with a statin drug lowers a type of inflammatory protein tied to cardiovascular disease (CVD) in people with HIV, according to a small study reported in the May 15 issue of the journal AIDS.

Inflammation in the blood vessels and elsewhere in the body has been tied directly to the development and worsening of CVD, both in people with HIV and those not living with the virus. Rates of CVD, however, are much higher in people with HIV and are rising over time as HIV-positive people reach their 50s and 60s.

Statin drugs are approved to treat high levels of low-density lipoprotein (LDL) cholesterol—and they do this quite well even in people with HIV—but one drug, Crestor (rosuvastatin), is also approved in HIV-negative people to lower a marker of inflammation tied to CVD—called high-sensitivity C-reactive protein (hsCRP). In a large study, treatment with Crestor lowered hsCRP levels, and that, in turn, lowered the risk of heart attacks and deaths.

To determine whether a statin—either Crestor or Pravachol (pravastatin)—could similarly reduce hsCRP levels in people with HIV, Elisabeth Aslangul, MD, from the Université Paris Descarte, and her colleagues analyzed blood samples of 58 people taking either 10 milligrams (mg) per day of Crestor or 40 mg of Pravachol as part of a larger study on the use of statins to lower LDL cholesterol.

Most of the study participants were white males, and the average age was 49. Ninety percent of the participants also had HIV levels under 400 copies, and overall the average CD4 count was 490. Aslangul and her colleagues measured hsCRP just before people began taking the statins and then again 45 days later.

The team found that both drugs reduced hsCRP levels by about 20 percent. Although Pravachol reduced LDL cholesterol by about half as much as Crestor, it actually beat Crestor in terms of hsCRP reductions—22 percent compared with 16 percent. In the large study used to approve Crestor to reduce hsCRP levels in HIV-negative people, the JUPITER trial, a higher dose reduced hsCRP levels by 37 percent over a two-year period. This led the authors to comment that “the fall in [hsCRP] observed here in HIV-infected patients during short-term statin therapy could be accentuated during long-term treatment.”

The authors acknowledge that their trial was small and of short duration, and that it did not have a control arm including people who received a placebo. Nevertheless, they point out that this is the first study to show a reduction in heart disease–causing inflammation, specifically hsCRP, by statin therapy in people with HIV.

“Clinical trials are warranted to determine the potential benefit of long-term statin treatment on the risk of cardiovascular events and death in at-risk HIV-infected patients,” they conclude.

Search: Statin, Crestor, rosuvastatin, Pravachol, pravastatin, hsCRP, high-sensitivity C-reactive protein, inflammation, Elisabeth Aslangul, Universite Descarte Paris


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    Hillcrester
    Ramona
    California


    Newhopenate
    New Hope
    Pennsylvania


    TaintedloveDC
    Washington
    DC


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.